Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

Ren, Xiaodan; Fu, Xue; He, Yuan-Qun; Li, Chunyan; Guo, Meng; Qiao, Min

doi:10.1097/md.0000000000031183

Cited by 8 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sofosbuvir/velpatasvir for example, which is a pangenotypic anti-HCV oral pellet conformulated with fixed-dose combinations of sofosbuvir 400 mg/velpatasvir 100 mg for adults, is indicated for chronic HCV genotype 1-6 infection without cirrhosis or with compensated cirrhosis and in combination with RBV for those with decompensated cirrhosis. The most common adverse reactions (≥ 10%, all grades) with sofosbuvir/velpatasvir in adults and pediatric patients 6 years of age and older were headache and fatigue; and when used with RBV in adults with decompensated cirrhosis were fatigue, anemia, nausea, headache, insomnia, and diarrhea [65][66][67].…”

Section: Pay Attention To Drug-drug Interactions (Ddis)mentioning

confidence: 99%

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

Xiong,

Guo

2024

Explor Dig Dis

View full text Add to dashboard Cite

Hepatitis C viral infections present a significant global health challenge, carrying substantial economic implications. These infections manifest in various clinical forms, including acute and chronic hepatitis, liver cirrhosis, hepatic failure, and hepatocellular carcinoma (HCC). Liver cirrhosis and HCC emerge as the primary contributors to mortality in hepatitis virus-induced liver diseases. To alleviate the public health impact of this disease, it is imperative to enhance the diagnosis and treatment rates among hepatitis C virus-infected individuals. The advent of direct-acting antivirals (DAAs), especially pan-genotypic regimens such as a combination of sofosbuvir and velpatasvir, has shown remarkable progress in achieving hepatitis C cure. However, potential obstacles, such as drug adverse effects and resistance-associated substitutions (RASs), warrant attention. Managing chronic hepatitis C (CHC) requires tailored treatment plans, vigilant monitoring, and judicious re-treatment strategies.

show abstract

Section: Pay Attention To Drug-drug Interactions (Ddis)mentioning

confidence: 99%

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

Xiong,

Guo

2024

Explor Dig Dis

View full text Add to dashboard Cite

show abstract

“…Velpatasvir was approved by the FDA in 2016 for use alongside sofosbuvir for treating patients infected with genotypes 1 to 6 [107]. High SVRs upon veltaspavir treatment were observed for all the genotypes, except in patients infected with genotype 3, where RBV was incorporated into the treatment.…”

Section: Velpatasvir and Pibrentasvirmentioning

confidence: 99%

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

Medina,

García,

Crespo

et al. 2023

CIMB

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a worldwide public health problem. Chronic infection with HCV can lead to liver cirrhosis or cancer. Although some immune-competent individuals can clear the virus, others develop chronic HCV disease due to viral mutations or an impaired immune response. IFNs type I and III and the signal transduction induced by them are essential for a proper antiviral effect. Research on the viral cycle and immune escape mechanisms has formed the basis of therapeutic strategies to achieve a sustained virological response (SVR). The first therapies were based on IFNα; then, IFNα plus ribavirin (IFN–RBV); and then, pegylated-IFNα-RBV (PEGIFNα-RIV) to improve cytokine pharmacokinetics. However, the maximum SVR was 60%, and several significant side effects were observed, decreasing patients’ treatment adherence. The development of direct-acting antivirals (DAAs) significantly enhanced the SVR (>90%), and the compounds were able to inhibit HCV replication without significant side effects, even in paediatric populations. The management of coinfected HBV–HCV and HCV–HIV patients has also improved based on DAA and PEG-IFNα-RBV (HBV–HCV). CD4 cells are crucial for an effective antiviral response. The IFNλ3, IL28B, TNF-α, IL-10, TLR-3, and TLR-9 gene polymorphisms are involved in viral clearance, therapeutic responses, and hepatic pathologies. Future research should focus on searching for strategies to circumvent resistance-associated substitution (RAS) to DAAs, develop new therapeutic schemes for different medical conditions, including organ transplant, and develop vaccines for long-lasting cellular and humoral responses with cross-protection against different HCV genotypes. The goal is to minimise the probability of HCV infection, HCV chronicity and hepatic carcinoma.

show abstract

“…Dodanie rybawiryny nie zwiększyło znacząco SVR u pacjentów z genotypem-1 oraz genotypem-2 HCV. Jednak schemat zawierający rybawirynę był lepszy pod względem wskaźnika SVR u pacjentów z genotypem 3 HCV [15]. Do tej pory sofosbuvir i velpatasvir plus RBV jest jedynym zatwierdzonym schematem pangenotypowym dla pacjentów z marskością wątroby związaną z HCV w stopniu Child-Pugh B i Child-Pugh C. Przeprowadzono badania podczas których wykazano, że wskaźniki SVR u pacjentów z marskością wątroby Child-Pugh B i Child-Pugh C otrzymujących SOF/VEL plus RBV przez 12 tygodni wynosiły odpowiednio 91,3% i 80% [16].…”

Section: Ive Velpatasvir -Inhibitor Ns5aunclassified

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

ABRAM¹,

Patryk

ADAMUS³

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction Cirrhosis is a condition in which the liver becomes fibrotic following damage to the liver and transforms the architecture of the organ into regenerative nodules. The disease is caused 30% by HCV infection, resulting in a risk of severe complications and death. Since the use of direct-acting antivirals ( DAAs) for the treatment of chronic HCV, sustained virological response (SVR) rates have begun to increase, even in treatment-resistant cases. Studies have also shown that DAAs may have applications in other viral diseases and even In the treatment of breast cancer. Aim of the study The purpouse of our study was to review scientific articles to show the efficiency and potential use of DAAs in the treatment of chronic HCV, and to identify possible directions for further research. Methods and materials We reviewed the English literature in the PubMed, using the key words: "simeprevir" ; "sofosbuvir" ; "velpatasvir" ; "telaprevir" ; "chronic hepatitis C". Results Studies have shown that the therapeutic regimens currently being designed with (DAAs) offer the possibility of treating almost the entire population with hepatitis C, while reducing side effects of interferon therapy such as increased AST, ALT activities, diarrhoea, vomiting, nausea and depression. They remain effective and tolerable, regardless of the stage of cirrhosis and associated serious co-morbidities. Analysis of studiem shows, that DAAs also show efficacy against other disease such as breast cancer, MRSA infections, SARS-CoV-2 or flavivirus infection. Conclusion All (DAAs) are effective in the treatment of patients with HCV, including cirrhosis. They result in significant improvements in prognosis and clinical outcomes. Promising results have been obtained in published data on the effect of DAAs against disease entities other than HCV, suggesting the rationale for future clinical trials to further the hypothesis of the increased potential of these drugs.

show abstract

Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

Cited by 8 publications

References 19 publications

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapy

A Synopsis of Hepatitis C Virus Treatments and Future Perspectives

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

Contact Info

Product

Resources

About